EDAP Announces Webcast and Conference Call of Second Quarter 2008 Results

* Reuters is not responsible for the content in this press release.

Tue Aug 5, 2008 1:46pm EDT 

LYON, France, Aug. 5, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the
global leader in therapeutic ultrasound, announced today details relating to its
second quarter 2008 earnings announcement, which will take place on Thursday,
August 21, 2008, before the opening of the market.

EDAP will hold a conference call on Thursday, August 21, 2008 at 8:30 a.m. ET to
discuss the results. The dial-in numbers are 1-888-241-0558 for domestic callers
and 1-647-427-3417 for international. The conference ID number for both is
59091975. A live Webcast of the conference call will be available online from
the investor relations page of the Company's new corporate Website at
www.edap-tms.com.

After the live Webcast, the call will remain available on EDAP's Website,
www.edap-tms.com, through November 21, 2008. In addition, a telephonic replay of
the call will be available until August 26, 2008. The replay dial-in numbers are
1-800-766-3146 for domestic callers and 1-402-220-7733 for international
callers. Please use event ID number 59091975.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically
proven choice for high-intensity focused ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized prostate
cancer (stages T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy treatment. Approved
in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity
Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S.
Phase II/III clinical trial under an Investigational Device Exemption granted by
the FDA. The Company also is developing this technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also produces and
commercializes medical equipment for treatment of urinary tract stones using
extra-corporeal shockwave lithotripsy (ESWL). For more information on the
company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and
http://www.pcaresearch.com or http://www.urotoday.com/HIFU.

-0-
CONTACT:  EDAP TMS SA
          Investor Relations / Legal Affairs
          Blandine Confort
          +33 4 72 15 31 72
          bconfort@edap-tms.com

          The Ruth Group
          Investors:
          R.J. Pellegrino
          646-536-7009
          rpellegrino@theruthgroup.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.